gms | German Medical Science

10th Malaria Meeting

Working party Malaria / Section Antiparasitic Chemotherapy of the Paul-Ehrlich-Society (PEG e.V.) in cooperation with the German Society for Tropical Medicine and International Health (DTG e.V.) and the German Society for Parasitology (DGP e.V.)

09.11. - 10.11.2012, Marburg an der Lahn

MMV’s drug development pipeline and strategies to move novel compounds into the clinic

Meeting Abstract

Search Medline for

  • J. J. Möhrle - Medicines for Malaria Venture, Geneva, Switzerland

10th Malaria Meeting. Marburg, 09.-10.11.2012. Düsseldorf: German Medical Science GMS Publishing House; 2013. Doc12mal09

doi: 10.3205/12mal09, urn:nbn:de:0183-12mal097

Published: January 8, 2013

© 2013 Möhrle.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

The global antimalarial pipeline has been strengthened in recent years with the delivery of new artemisinin combination therapies, promising new clinical candidates and early stage discovery projects. This talk will focus on the challenges that remain and the strategy adopted by Medicines for Malaria Venture (MMV) in targeting eradication. MMV’s focus has shifted from the treatment of blood stage malaria infections and now also includes relapse prevention, blocking of transmission and the protection of vulnerable populations in areas with little or no transmission.

New target product profiles and target candidate profiles defining the specific characteristics of individual molecules for asexual blood stage cures, transmission blocking, vivax and chemoprotection will be described.

Finally strategies will be presented how obtain earlier information and confirmation on antimalarial activity in humans.